BiotechTube
Home/Pipeline/Biomarker Analysis for Breast Cancer

Biomarker Analysis for Breast Cancer

Breast Cancer

ResearchActive

Key Facts

Indication
Breast Cancer
Phase
Research
Status
Active
Company
OTraces

About OTraces

OTraces is an early-stage biotech company building a versatile diagnostic platform focused on early disease detection through non-invasive sampling. Its core technology uses advanced computational methods to analyze biomarkers in the tumor microenvironment and other biological signals, claiming over 95% accuracy for various indications, with a highlighted 98.6% accuracy for a prostate cancer test. The company operates as a B2B co-development partner for diagnostic and therapeutic developers, aiming to integrate its analytical tools into existing workflows to enhance diagnostic precision and enable earlier intervention.

View full company profile

Therapeutic Areas

OncologyChronic Diseases

Other Breast Cancer Drugs

DrugCompanyPhase
Antifibrotic Therapy ProgramMeCo DiagnosticsPre-clinical
inPROBE for HER2SDS OpticClinical Investigation
ACT‑BC1AnthrocellPreclinical
APA-1000 Breast Thermotherapy SystemMedifocusPhase III
Early‑Detection Breast Cancer ScreeningKarkinos HealthcareMarket
Unnamed Breast Cancer ProgramClick TherapeuticsPilot/Phase 2
Lerociclib (Lerocliclib)Chemogenics BioPharmaPhase 3
AT-017Asieris PharmaceuticalsNot Specified
CDK2 inhibitorAcelleraPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Maveropepimut-S (MVP-S)BioVaxysClinical Evaluation
Cannabics® BRST-33CNBX PharmaceuticalsDiscovery